A brief overview of tyrosine Hydroxylase and α-synuclein in the Parkinsonian brain

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 4, 2012, Pages 456-462

  Khan, Wajihullah ^a   Priyadarshini, Medha ^b   Zakai, Haytham A ^a   Kamal, Mohammad A ^a   Alam, Qamre ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Alpha synuclein; Dopamine; Neurodegeneration; Nigrostriatal pathway; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

ADRENALIN; ALPHA SYNUCLEIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CATECHOLAMINE; DOPAMINE; IMMUNOLIPOSOME; LEVODOPA; MACROGOL; NORADRENALIN; TRANSFERRIN RECEPTOR; TYROSINE 3 MONOOXYGENASE;

BIOTRANSFORMATION; BLOOD BRAIN BARRIER; BRAIN REGION; CATALYSIS; CELL DEATH; COMPETITIVE INHIBITION; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENE TRANSFER; HUMAN; LIPOSOMAL DELIVERY; MISSENSE MUTATION; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; STRUCTURE ACTIVITY RELATION; UPREGULATION;

EID: 84862567466     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800792929     Document Type: Review

References (62)

1. Booij, J.; Bergmans, P.; Winogroolzka, A.; Speelman, J.D.; Wolters, E.C. Imaging of dopamine transporters with [123I] Fp-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse, 2001, 39, 101-108.
2. Christakos, C.N.; Erimaki, S.; Anagnostou, E.; Anastasopoulos, D. Tremor-related motor unit firing in Parkinson's disease: implications for tremor genesis. J. Physiol. Lond., 2009, 587, 4811-4827.
3. Hallet, M. Bradykinesia: Why do Parkinson's patients have it and what trouble does it cause? Mov. Disord., 2011, 26, 1579-1581.
4. Allen, N.E.; Sherrington, C.; Paul, S.S.; Canning, C.G. Balance and fall in Parkinson's Disease: A Meta-analysis of the effect of exercise and motor training. Mov. Disord., 2011, 26, 1605-1615.
5. Zhong, N.; Christina, Y.K.; Rizzu, P.; Guela, C.; Douglas, R.P.; Emanuel, N.P.; Feridinando, S.; Peter, H. DJ-1 transcriptionally up regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein associated splicing factor. J. Biol. Chem., 2006, 281, 20940-20948.
6. Sutoo, D.; Akiyama, K.; Yabe, K. Quantitative imaging of tyrosine hydroxylase and calmodulin in the human brain. J. Neurosci. Res., 2001, 63, 369-376.
7. Willemsen, M.A.; Verbeek, M.M.; Kamsteeg, E-J.; de Rijk van Andel, J.F.; Aeby, A.; Blau, N. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain, 2010, 133, 1810-1822
8. Nagatsu, T.; Levitt, M.; Udenfriend, S. Tyrosine hydroxylase: The initial step in norepinephrine synthesis. J. Biol. Chem., 1964, 239, 2910-2917.
9. Flatmark, T.; Stevens, R.C. Structural insight into the aromatic amino acid hydroxylases and their disease-related mutant forms. Chem. Rev., 1999, 99, 2137-2160.
10. Nagatsu, T. Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. Essays Biochem., 1995, 30, 15-35.
11. Nakashima, A.; Hayashi, N.; Kaneko, Y.S.; Mori, K.; Sabban, E.L.; Nagatsu, T.; Ota, A. Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines. J. Neural Transm., 2009, 116(11), 1355-1362.
12. Cotzias, G.C.; Van Woert, M.H.; Schiffer, L.M. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med., 1967, 276, 374-379.
13. Zhang, D.; Kanthasamy, A.; Yang, Y.; Anantharam, V.; Kanthasamy, A. Protein kinase c negatively regulates tyrosine hydroxylase activity and dopamine synthesis by enhancing protein phosphatase-2a activity in dopaminergic neurons. J. Neurosci., 2007, 27, 5349-5362.
14. Akira, N.; Yoko, S.K.; Keiji, M.; Kentaro, F.; Toshimitsu, T.; Takahiro, S.; Toshiharu, N.; Akira O. The mutation of two amino acid residues in the N-terminus of tyrosine hydroxylase (TH) dramatically enhances the catalytic activity in neuro endocrine At T-20 cells. J. Neurochem., 2002, 82, 202-206.
15. Haavik, J.; Tosaka, K. Tyrosine hydroxylase and Parkinson's disease. Mol. Neurobiol., 1998, 16, 285-309.
16. Wong, D.L.; Tank, A.W. Stress-induced catecholaminergic function: transcriptional and post-transcriptional control. Stress, 2007, 10, 121-130.
17. Zafeiriou, D.I.; Willemsen, M.A.; Verbeek, M.M.; Vargiami, E.; Ververi, A.; Wevers, R. Tyrosine hydroxylase deficiency with severe clinical course. Mol. Genet. Metab., 2009, 97, 18-20.
18. Castaigne, P.; Rondont, P.; Ribadeau-Dumas, L.J.; Said, G. Progressive extrapyramidal disorder in 2 young brothers. Remarkable effect of treatment with L-dopa. Rev. Neurol., 1971, 124, 162-166.
19. Rondent, P.; Ziegler, M. Dystonia-L-dopa responsive or juvenile parkinsonism? J. Neurol. Transm. Suppl., 1983, 19, 273-281.
20. Rongont, P.; Aicardi, F.; Goutieres Ziegler, M. Dopa-sensitive dystonia. Rev. Neurol., 1992, 148, 680-686.
21. Hoffmann, G.F.; Assmann, B.; Brautigam, C.; Dionisi-Vici, C.; Housler, M.; De Klerk, J.B.; Naumann, M.; Strassburg, H.M.; Wevers, R.A. Tyrosine hydroxylase deficiency causes progressive enceph alopathy and dopanonresponsive dystonia. Ann. Neurol., 2003, 54, 56-65.
22. Goldstein, M.; Wu, J.; Filer, D.; Friedhoff, A.J. Genetically Modified Tyrosine Hydroxylase and Uses Thereof Patent, 1994, 5300436.
23. Lang, A.E.; Lozano, A.M. Parkinson disease. N. Engl. J. Med., 1998, 339, 1044-1053.
24. Kaushik, P.; Gorin, F.; Vali, S. Dynamics of Tyrosine hydroxylase mediated regulation of dopamine synthesis. J. Comput. Neurosci., 2007, 22, 147-160.
25. Javoy-Agid, F.; Hirsch, A.C.; Dumas, S.; Duyckaerts, C.; Mallet, J.; Agid, Y. Decreased tyrosine hydroxylase messanger RNA in the surviving dopamine neurons of the substantia ingrain Parkinson disease: An in situ hybridization study. Neuroscience, 1990, 38, 245-253.
26. Maroteaux, L.; Campanelli, J.T.; Scheller, R.H. Synuclein: A neuron specific protein localized to the nucleus and pre-syneptic nerve terminal. J. Neurosci., 1988, 8, 2804-2815.
27. George, R.J.; W. Haycock,Johnson, J.P.; Craviso, G.L.; Waymire, J.W. In vitro phosphorylation of bovine adrenalchromaffin cell tyrosine hydroxylase by endoginous protein kinase. J. Neurosci., 1989, 52, 247-284.
28. Perez, R.G.; Hastings, T.G. Could a loss of Alpha-synuclein function put dopaminergic neurons at risk? Neurochemistry, 2004, 89, 1318-1324.
29. Shun, Y.; Ziaohong, Z.; Yaohua, L.; Chen, Z.; Ming, Z.; Zhang, Y.A.; Ueda, K.; Chan, P. Inhibition of tyrosine hydroxylase expression in α-synuclein-transfected dopaminergic neuronal cells. Neurosci. Lett., 2004, 367, 34-37.
30. Georg, T.M. The synuclein. Gen. Biol., 2001, 3, 30021-30026.
31. Ma, Q.L.; Chen, P.; Yoshi, M.; Ueda, K. α-synuclein aggregation and neurodegenerative diseases. J. Alzheimer's Dis., 2003, 5, 139-148.
32. Ueda, K.; Fukushima, H.; Masliah, E.; Zia, Y.; Iwai, A.; oshimoto, M.; Otero, D.A.; Kondo, J.; Ihara, Y.; Saitosh, T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer's disease. Proc. Natt. Acad. Sci. USA, 1993, 90, 11282-11286.
33. Gwinn, K. Genetics and Parkinson's disease: What have we learned? Newslett. News Rev., 2009.
34. Masliah, E.; Rockesteinf, F.; Veinbergs, I.; Mallory, M.; Hoishimoto, M.; Takeda, A.; Sagara, Y.; Sick, A.; Mucke, L. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science, 2000, 287, 1265-1269.
35. Kirik, D.; Rosenblad, C.; Burger, C.; Lundberg, C.; Johansen, T.E.; muzyczka, N.; Mandel, R.J.; Bijorklund, A. Parkinson like neurodegeneration induced by targeted overexpression of α- synuclein in the nigrostriatal system. Neuroscience, 2002, 22, 2780-2790.
36. McNaught, K.S.; Belizaire, R.; Isacson, O.; Jenner, P.; Olanow, C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol., 2003, 179, 38-46.
37. Shimura, H.; Hattori, N.; Kubo, S.; Mizuno, Y.; Asakawa, A.; Minoshima, S.; Shimizu, N.; Iwai, K.T.; Chiba, T.; Tanaka, K.; Suzuki, T. Familial Parkinson's disease gene product, Parkin, is a ubiquitin-protein ligase. Nat. Genet., 2000, 25, 302-305.
38. Chiba-Falek, O.; Nussbaum, R.L. Effect of allelic variation at the NACP-Rap 1 repeat upstream of the α-synuclein gene (SNCA) on transcription in a cell culture luci ferase reporter system. Hum. Mol. Genet., 2001, 10, 3101-3109.
39. Xiangmin, M.P.; Roya, T.; Paula, D.; Leonidas, S.; Perez, R.G. α- synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J. Cell. Sci., 2005, 118, 3523-3530.
40. McLaught, K.S.; Olanow, C.W.; Halliwell, B.; Isacson, O.; Jenner, P. Failure of ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci., 2001, 2, 589-594.
41. Hsu, L.J.; Sagara, Y.; Arroyo, A.; Rockenstein, E.; Sisk, A.; Mallory, M.; Wong, J.; Takenouchi, T.; Hoshomoti, M.; Masliah, E. Alpha-Synuclein promotes mitochondrial deficit, oxidative stress. Am. J. Pathol., 2000, 157, 401-410.
42. Junn, M.; Mouradian, M.M. Human α-synuclein over expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett., 2002, 320, 146-150.
43. Feany, M.B.; Bender, W.W. Drosophila model of Parkinson's disease. Nature, 2000, 404, 394-398.
44. Kruger, R.; Cohn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S.; Przuntek, H.; J.T. Epplen, Scholas, L.; O. Riess, O. Ala 30 premutation in the gene encoding synuclein in Parkinson's disease. Nat. Genet., 1998, 18,106-108.
45. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ade, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E.S.; Chandrashekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W.G.; Lazzarini, A.M.; Duvosini, R.C.; Lorio, G.; Golhe, L.I.; Nussbaum, R.L. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science, 1997, 2045-2047.
46. Chan, P.; Xiang, X.; Forno, L.S.; Monte, D.A.D.; Tanner, C.M.; Langstone, J.W. Absence of mutation in the coding region of the α-synuclein gene in pathologically proven Parkinson disease. Neurology, 1998, 50, 1136-1137.
47. Chan, P.; Tanner, C.M.; Xiang, X.; Langstone, J.W. Failure to find the-synucle- In gene missence mutation (G209A) in 100 patients with younger onset of Parkinson's disease. Neurology, 1998, 50, 513-514.
48. Arima, K.; Ueda, K.; Sunohara, N.; Hirai, S.; Y. Izumiyama, Tomozuka-Uehara, H.; Kawai, M. Immuno electron microscopic demonstration of NACP/Alpha-nuclein epitopes on the filamentous components of Lewy bodies in Parkinso's disease and in dementia with Lewy bodies. Brain Res., 1998, 808, 93-100.
49. Baba, M.; Nakajo, S.; Tu, P.H.; Tomita, T.; Nakaya, K.; Lee, V.M.; Trojanowski, J.Q.; Iwatsubo, T. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's Disease and dementia with Lewy bodies. Am. J. Pathol., 1998, 152, 879-884.
50. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. α-synuclein in lewy bodies. Nature, 1997, 388, 839-840.
51. Braak, H.; Del, K.; Tredici, U.; Rub, R.A.; de Vos, E.N.; Steur, J.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 2003, 24, 197-211.
52. Goedert, M. Alpha-synuclein and neurodegeneration. Nat. Rev. Neurosci., 2001, 2, 492-501.
53. Manning-Bog, A.B.; McCommarck, A.L.; Lee, J.; Uversky, V.N.; Fink, A.L.; Monte, D.A.D. The herbicide paraquat causes upregulation and aggregation ofα-syn in mice: Paraquat and alpha nuclein. J. Bil. Chem., 2002, 277, 1641-1644.
54. Vila, M.; Vacosavic, S.; Jackson-Lewis, V.; Neystart, M.; Jakowec, M.; Perzedborsky, S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neuron following administration of the Parkinson toxin MPTR. J. Neurochem., 2000, 74, 721-729.
55. Nagatsu, T.; Hirata, Y. Inhibition of tyrosine hydroxylase system by MPTP, 1-methyl-4-phenyl-pyridinium ion (MPP+) and the structurally related compounds in vitro and in vivo. Eur. Neurol., 1987, 26, 11-15.
56. Betarbet, R.; Canet-Aviles, R.M.; Sherer, T.B.; Mastroberardino, P.G.; McLendon, C.; Kim, J.H.; Lund, S.; Na, H.M.; Taylor, G.; Bence, N.F.; Kopito, R.; Seo, B.B.; Yagi, T.; Yagi, A.; Klinefelter, G.; Cookson, M.R.; Greenamyre, T.J. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis., 2006, 22, 404-420.
57. Blackinton, J.; Lakshminarasimhan, M.; Thomson, K.J.; Ahmad, R.; Gregio, E.; Raza, A.S.; Cookson, M.R.; Wilson, M.A. Formation of a Stabilized Cysteine-sulfinic Acid Is Critical for the Mitochondrial Function of the Parkinsonism Protein DJ. J. Biol. Chem., 2009, 284, 6476-6485.
58. Bonifati, V.; Rizzu, P.; Van barren, M.J.; Schaap, O.; Breedveld, G.J.; Krieger, E.; Dekker, M.C.; Squitieri, F.; Ibanez, P.; Joosse, M.; van Dongen, J.W.; Vanacore, N.; van Swieten, J.C.; Brice, A.; Meco, G.; van Duijn, C.M.; Oostra, B.A.; Heutink, P. Mutation in the DJ-1 gene associated with autosomal ressesive early onset of Parkinsonism. Science, 2003, 299, 256-259.
59. Barnham, J.K.; Masters, A.B.; Bush, A. Neurodegenerative disease and oxidative stress. Nature Rev. Drug Discovery, 2004, 3, 205-214.
60. Kish, J.; Shanak, K.; Hornykiewicz, O. Uneven pattern of dopamine-producing adrenal medullary tissue to the striatum of the patients with idiopathic Parkinson's disease. N. Engl. J. Med.,1988, 318, 876-880.
61. William, M.P. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. Neur. Rx. 2005, 2, 129-138.
62. Goldstein, M.; Filer, D.; Friedhoff, A.; Wu, J. Genetically modified tyrosine hydroxyls for DOPA production in the treatment of Parkinson's disease. Patent filed by Neurochemistry Research Laboratory and Millhouse Laboratories, Department of Psychiatry New York University School of Medicine.